nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Pain—Ifosfamide—testicular cancer	0.00242	0.00242	CcSEcCtD
Darifenacin—Loss of consciousness—Etoposide—testicular cancer	0.00241	0.00241	CcSEcCtD
Darifenacin—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00241	0.00241	CcSEcCtD
Darifenacin—Nervous system disorder—Cisplatin—testicular cancer	0.00239	0.00239	CcSEcCtD
Darifenacin—Cough—Etoposide—testicular cancer	0.00239	0.00239	CcSEcCtD
Darifenacin—Tachycardia—Cisplatin—testicular cancer	0.00238	0.00238	CcSEcCtD
Darifenacin—Asthenia—Bleomycin—testicular cancer	0.00237	0.00237	CcSEcCtD
Darifenacin—Skin disorder—Cisplatin—testicular cancer	0.00237	0.00237	CcSEcCtD
Darifenacin—Hypertension—Etoposide—testicular cancer	0.00236	0.00236	CcSEcCtD
Darifenacin—Hyperhidrosis—Cisplatin—testicular cancer	0.00236	0.00236	CcSEcCtD
Darifenacin—Pruritus—Bleomycin—testicular cancer	0.00234	0.00234	CcSEcCtD
Darifenacin—Dry skin—Epirubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Darifenacin—Feeling abnormal—Ifosfamide—testicular cancer	0.00233	0.00233	CcSEcCtD
Darifenacin—Nausea—Vinblastine—testicular cancer	0.00233	0.00233	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00231	0.00231	CcSEcCtD
Darifenacin—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00231	0.00231	CcSEcCtD
Darifenacin—Breast disorder—Epirubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.00229	0.00229	CcSEcCtD
Darifenacin—Face oedema—Doxorubicin—testicular cancer	0.00228	0.00228	CcSEcCtD
Darifenacin—Hypersensitivity—Dactinomycin—testicular cancer	0.00227	0.00227	CcSEcCtD
Darifenacin—Confusional state—Etoposide—testicular cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00225	0.00225	CcSEcCtD
Darifenacin—Abdominal pain—Ifosfamide—testicular cancer	0.00224	0.00224	CcSEcCtD
Darifenacin—Anaphylactic shock—Etoposide—testicular cancer	0.00223	0.00223	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00222	0.00222	CcSEcCtD
Darifenacin—Infection—Etoposide—testicular cancer	0.00222	0.00222	CcSEcCtD
Darifenacin—Asthenia—Dactinomycin—testicular cancer	0.00221	0.00221	CcSEcCtD
Darifenacin—Influenza—Epirubicin—testicular cancer	0.0022	0.0022	CcSEcCtD
Darifenacin—Tachycardia—Etoposide—testicular cancer	0.00218	0.00218	CcSEcCtD
Darifenacin—Dyspnoea—Cisplatin—testicular cancer	0.00217	0.00217	CcSEcCtD
Darifenacin—Skin disorder—Etoposide—testicular cancer	0.00217	0.00217	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—testicular cancer	0.00217	0.00217	CcSEcCtD
Darifenacin—Dry skin—Doxorubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Darifenacin—Hyperhidrosis—Etoposide—testicular cancer	0.00216	0.00216	CcSEcCtD
Darifenacin—Breast disorder—Doxorubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Darifenacin—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.00212	0.00212	CcSEcCtD
Darifenacin—Bronchitis—Epirubicin—testicular cancer	0.00212	0.00212	CcSEcCtD
Darifenacin—Diarrhoea—Dactinomycin—testicular cancer	0.00211	0.00211	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00211	0.00211	CcSEcCtD
Darifenacin—Vomiting—Bleomycin—testicular cancer	0.0021	0.0021	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—testicular cancer	0.0021	0.0021	CcSEcCtD
Darifenacin—Infestation—Methotrexate—testicular cancer	0.0021	0.0021	CcSEcCtD
Darifenacin—Rash—Bleomycin—testicular cancer	0.00209	0.00209	CcSEcCtD
Darifenacin—Pain—Cisplatin—testicular cancer	0.00209	0.00209	CcSEcCtD
Darifenacin—Dermatitis—Bleomycin—testicular cancer	0.00209	0.00209	CcSEcCtD
Darifenacin—Hypersensitivity—Ifosfamide—testicular cancer	0.00208	0.00208	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00208	0.00208	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—testicular cancer	0.00205	0.00205	CcSEcCtD
Darifenacin—Influenza—Doxorubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Darifenacin—Asthenia—Ifosfamide—testicular cancer	0.00203	0.00203	CcSEcCtD
Darifenacin—Sweating—Methotrexate—testicular cancer	0.00201	0.00201	CcSEcCtD
Darifenacin—Feeling abnormal—Cisplatin—testicular cancer	0.00201	0.00201	CcSEcCtD
Darifenacin—Weight increased—Epirubicin—testicular cancer	0.002	0.002	CcSEcCtD
Darifenacin—Pruritus—Ifosfamide—testicular cancer	0.002	0.002	CcSEcCtD
Darifenacin—Dyspnoea—Etoposide—testicular cancer	0.00199	0.00199	CcSEcCtD
Darifenacin—Somnolence—Etoposide—testicular cancer	0.00199	0.00199	CcSEcCtD
Darifenacin—Nausea—Bleomycin—testicular cancer	0.00197	0.00197	CcSEcCtD
Darifenacin—Infestation—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Darifenacin—Infestation NOS—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Darifenacin—Vomiting—Dactinomycin—testicular cancer	0.00196	0.00196	CcSEcCtD
Darifenacin—Bronchitis—Doxorubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Darifenacin—Rash—Dactinomycin—testicular cancer	0.00195	0.00195	CcSEcCtD
Darifenacin—Diarrhoea—Ifosfamide—testicular cancer	0.00194	0.00194	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Etoposide—testicular cancer	0.00193	0.00193	CcSEcCtD
Darifenacin—Stomatitis—Epirubicin—testicular cancer	0.00191	0.00191	CcSEcCtD
Darifenacin—Pain—Etoposide—testicular cancer	0.00191	0.00191	CcSEcCtD
Darifenacin—Constipation—Etoposide—testicular cancer	0.00191	0.00191	CcSEcCtD
Darifenacin—Urinary tract infection—Epirubicin—testicular cancer	0.00191	0.00191	CcSEcCtD
Darifenacin—Sweating—Epirubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Darifenacin—Dizziness—Ifosfamide—testicular cancer	0.00187	0.00187	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—testicular cancer	0.00187	0.00187	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—testicular cancer	0.00186	0.00186	CcSEcCtD
Darifenacin—Weight increased—Doxorubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—testicular cancer	0.00185	0.00185	CcSEcCtD
Darifenacin—Sinusitis—Epirubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Darifenacin—Feeling abnormal—Etoposide—testicular cancer	0.00184	0.00184	CcSEcCtD
Darifenacin—Nausea—Dactinomycin—testicular cancer	0.00183	0.00183	CcSEcCtD
Darifenacin—Gastrointestinal pain—Etoposide—testicular cancer	0.00183	0.00183	CcSEcCtD
Darifenacin—Infestation NOS—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Darifenacin—Infestation—Doxorubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—testicular cancer	0.00182	0.00182	CcSEcCtD
Darifenacin—Vomiting—Ifosfamide—testicular cancer	0.0018	0.0018	CcSEcCtD
Darifenacin—Hypersensitivity—Cisplatin—testicular cancer	0.0018	0.0018	CcSEcCtD
Darifenacin—Rash—Ifosfamide—testicular cancer	0.00178	0.00178	CcSEcCtD
Darifenacin—Dermatitis—Ifosfamide—testicular cancer	0.00178	0.00178	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—testicular cancer	0.00178	0.00178	CcSEcCtD
Darifenacin—Stomatitis—Doxorubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Darifenacin—Rhinitis—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Darifenacin—Abdominal pain—Etoposide—testicular cancer	0.00177	0.00177	CcSEcCtD
Darifenacin—Urinary tract infection—Doxorubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—testicular cancer	0.00176	0.00176	CcSEcCtD
Darifenacin—Asthenia—Cisplatin—testicular cancer	0.00175	0.00175	CcSEcCtD
Darifenacin—Pharyngitis—Epirubicin—testicular cancer	0.00175	0.00175	CcSEcCtD
Darifenacin—Sweating—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Darifenacin—Urinary tract disorder—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Darifenacin—Oedema peripheral—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Darifenacin—Urethral disorder—Epirubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—testicular cancer	0.00171	0.00171	CcSEcCtD
Darifenacin—Sinusitis—Doxorubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Darifenacin—Visual impairment—Epirubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—testicular cancer	0.0017	0.0017	CcSEcCtD
Darifenacin—Nausea—Ifosfamide—testicular cancer	0.00168	0.00168	CcSEcCtD
Darifenacin—Diarrhoea—Cisplatin—testicular cancer	0.00167	0.00167	CcSEcCtD
Darifenacin—Erythema multiforme—Epirubicin—testicular cancer	0.00167	0.00167	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—testicular cancer	0.00165	0.00165	CcSEcCtD
Darifenacin—Eye disorder—Epirubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Darifenacin—Hypersensitivity—Etoposide—testicular cancer	0.00165	0.00165	CcSEcCtD
Darifenacin—Rhinitis—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Darifenacin—Pharyngitis—Doxorubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Darifenacin—Urinary tract disorder—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Darifenacin—Oedema peripheral—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—testicular cancer	0.00161	0.00161	CcSEcCtD
Darifenacin—Asthenia—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Darifenacin—Angiopathy—Epirubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Darifenacin—Urethral disorder—Doxorubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Darifenacin—Mediastinal disorder—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Darifenacin—Back pain—Methotrexate—testicular cancer	0.00159	0.00159	CcSEcCtD
Darifenacin—Pruritus—Etoposide—testicular cancer	0.00158	0.00158	CcSEcCtD
Darifenacin—Visual impairment—Doxorubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Darifenacin—Vomiting—Cisplatin—testicular cancer	0.00155	0.00155	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—testicular cancer	0.00155	0.00155	CcSEcCtD
Darifenacin—Mental disorder—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Darifenacin—Erythema multiforme—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Darifenacin—Rash—Cisplatin—testicular cancer	0.00154	0.00154	CcSEcCtD
Darifenacin—Dermatitis—Cisplatin—testicular cancer	0.00154	0.00154	CcSEcCtD
Darifenacin—Diarrhoea—Etoposide—testicular cancer	0.00153	0.00153	CcSEcCtD
Darifenacin—Eye disorder—Doxorubicin—testicular cancer	0.00152	0.00152	CcSEcCtD
Darifenacin—Flatulence—Epirubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Darifenacin—Dysgeusia—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Darifenacin—Back pain—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Darifenacin—Angiopathy—Doxorubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Darifenacin—Dizziness—Etoposide—testicular cancer	0.00148	0.00148	CcSEcCtD
Darifenacin—Mediastinal disorder—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Darifenacin—Nausea—Cisplatin—testicular cancer	0.00145	0.00145	CcSEcCtD
Darifenacin—Vision blurred—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Darifenacin—Cough—Methotrexate—testicular cancer	0.00143	0.00143	CcSEcCtD
Darifenacin—Mental disorder—Doxorubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Darifenacin—Vomiting—Etoposide—testicular cancer	0.00142	0.00142	CcSEcCtD
Darifenacin—Rash—Etoposide—testicular cancer	0.00141	0.00141	CcSEcCtD
Darifenacin—Dermatitis—Etoposide—testicular cancer	0.00141	0.00141	CcSEcCtD
Darifenacin—Headache—Etoposide—testicular cancer	0.0014	0.0014	CcSEcCtD
Darifenacin—Flatulence—Doxorubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Darifenacin—Dysgeusia—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00139	0.00139	CcSEcCtD
Darifenacin—Syncope—Epirubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Darifenacin—Back pain—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Darifenacin—Palpitations—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—testicular cancer	0.00135	0.00135	CcSEcCtD
Darifenacin—Loss of consciousness—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Darifenacin—Cough—Epirubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Darifenacin—Vision blurred—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Darifenacin—Infection—Methotrexate—testicular cancer	0.00133	0.00133	CcSEcCtD
Darifenacin—Nausea—Etoposide—testicular cancer	0.00133	0.00133	CcSEcCtD
Darifenacin—Hypertension—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Darifenacin—Arthralgia—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Darifenacin—Dry mouth—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Darifenacin—Syncope—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Darifenacin—Confusional state—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Darifenacin—Palpitations—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Darifenacin—Anaphylactic shock—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Darifenacin—Oedema—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Darifenacin—Loss of consciousness—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Darifenacin—Infection—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Darifenacin—Cough—Doxorubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Darifenacin—Shock—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Darifenacin—Nervous system disorder—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Darifenacin—Hypertension—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Darifenacin—Tachycardia—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00122	0.00122	CcSEcCtD
Darifenacin—Skin disorder—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Darifenacin—Hyperhidrosis—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Darifenacin—Arthralgia—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Darifenacin—Dry mouth—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—testicular cancer	0.00118	0.00118	CcSEcCtD
Darifenacin—Confusional state—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Darifenacin—Anaphylactic shock—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Darifenacin—Oedema—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Darifenacin—Infection—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Darifenacin—Pain—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Darifenacin—Shock—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Darifenacin—Nervous system disorder—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Darifenacin—Insomnia—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Darifenacin—Tachycardia—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Darifenacin—Skin disorder—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Darifenacin—Hyperhidrosis—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Darifenacin—Dyspnoea—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Darifenacin—Somnolence—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Darifenacin—Dyspepsia—Epirubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Darifenacin—Constipation—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Darifenacin—Pain—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Darifenacin—Insomnia—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Darifenacin—Dyspnoea—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Darifenacin—Feeling abnormal—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Darifenacin—Somnolence—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Darifenacin—Gastrointestinal pain—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Darifenacin—Dyspepsia—Doxorubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Darifenacin—Pain—Doxorubicin—testicular cancer	0.000991	0.000991	CcSEcCtD
Darifenacin—Constipation—Doxorubicin—testicular cancer	0.000991	0.000991	CcSEcCtD
Darifenacin—Abdominal pain—Epirubicin—testicular cancer	0.00099	0.00099	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—testicular cancer	0.000986	0.000986	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—testicular cancer	0.00096	0.00096	CcSEcCtD
Darifenacin—Feeling abnormal—Doxorubicin—testicular cancer	0.000955	0.000955	CcSEcCtD
Darifenacin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000948	0.000948	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—testicular cancer	0.000947	0.000947	CcSEcCtD
Darifenacin—Hypersensitivity—Epirubicin—testicular cancer	0.000923	0.000923	CcSEcCtD
Darifenacin—Abdominal pain—Doxorubicin—testicular cancer	0.000916	0.000916	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—testicular cancer	0.000916	0.000916	CcSEcCtD
Darifenacin—Asthenia—Epirubicin—testicular cancer	0.000899	0.000899	CcSEcCtD
Darifenacin—Pruritus—Epirubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—testicular cancer	0.000885	0.000885	CcSEcCtD
Darifenacin—Diarrhoea—Epirubicin—testicular cancer	0.000857	0.000857	CcSEcCtD
Darifenacin—Hypersensitivity—Doxorubicin—testicular cancer	0.000854	0.000854	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—testicular cancer	0.000851	0.000851	CcSEcCtD
Darifenacin—Rash—Methotrexate—testicular cancer	0.000844	0.000844	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—testicular cancer	0.000843	0.000843	CcSEcCtD
Darifenacin—Headache—Methotrexate—testicular cancer	0.000838	0.000838	CcSEcCtD
Darifenacin—Asthenia—Doxorubicin—testicular cancer	0.000831	0.000831	CcSEcCtD
Darifenacin—Dizziness—Epirubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Darifenacin—Pruritus—Doxorubicin—testicular cancer	0.00082	0.00082	CcSEcCtD
Darifenacin—Vomiting—Epirubicin—testicular cancer	0.000796	0.000796	CcSEcCtD
Darifenacin—Nausea—Methotrexate—testicular cancer	0.000795	0.000795	CcSEcCtD
Darifenacin—Diarrhoea—Doxorubicin—testicular cancer	0.000793	0.000793	CcSEcCtD
Darifenacin—Rash—Epirubicin—testicular cancer	0.00079	0.00079	CcSEcCtD
Darifenacin—Dermatitis—Epirubicin—testicular cancer	0.000789	0.000789	CcSEcCtD
Darifenacin—Headache—Epirubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Darifenacin—Dizziness—Doxorubicin—testicular cancer	0.000766	0.000766	CcSEcCtD
Darifenacin—Nausea—Epirubicin—testicular cancer	0.000744	0.000744	CcSEcCtD
Darifenacin—Vomiting—Doxorubicin—testicular cancer	0.000737	0.000737	CcSEcCtD
Darifenacin—Rash—Doxorubicin—testicular cancer	0.000731	0.000731	CcSEcCtD
Darifenacin—Dermatitis—Doxorubicin—testicular cancer	0.00073	0.00073	CcSEcCtD
Darifenacin—Headache—Doxorubicin—testicular cancer	0.000726	0.000726	CcSEcCtD
Darifenacin—Nausea—Doxorubicin—testicular cancer	0.000688	0.000688	CcSEcCtD
